Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β-cells of the pancreas along with insulin, after a meal. Like insulin, amylin is completely absent in individuals with Type I diabetes.
CAT No: 10-101-28
CAS No:151126-32-8
Synonyms/Alias:AC 0137; AC 137; Symlin; Tripro-Amylin; riproamylin; Pramlintide; LS-181996; LS181996; Amylin
Pramlintide is a synthetic peptide analog of human amylin, a naturally occurring hormone co-secreted with insulin by pancreatic β-cells. Structurally, it consists of 37 amino acids and incorporates specific amino acid substitutions to enhance its stability and solubility relative to native amylin. As a peptide compound, pramlintide is widely recognized for its ability to mimic the physiological actions of amylin, particularly in the regulation of postprandial glucose levels, modulation of gastric emptying, and suppression of glucagon secretion. Its unique biochemical properties and structural features make it a valuable tool for advancing peptide research, metabolic studies, and the exploration of amylin receptor pharmacology.
Peptide hormone research: Pramlintide serves as a robust model system for investigating the structure-function relationships of amylin and related peptide hormones. Its engineered amino acid sequence allows researchers to dissect the molecular determinants of receptor binding, aggregation propensity, and biological activity. By comparing pramlintide to native amylin and other analogs, scientists can elucidate the mechanisms underlying peptide hormone stability, receptor selectivity, and downstream signaling, thereby informing the rational design of next-generation peptide therapeutics and research probes.
Metabolic regulation studies: The compound is extensively used in experimental models to investigate the physiological roles of amylin in glucose homeostasis and energy balance. Its ability to modulate gastric emptying, suppress postprandial glucagon secretion, and influence satiety makes it a valuable reagent for metabolic research. By administering pramlintide in in vitro or in vivo settings, researchers can probe the pathways involved in nutrient sensing, appetite regulation, and glycemic control, generating insights into the interplay between pancreatic peptides and systemic metabolism.
Peptide aggregation and amyloidogenesis research: Due to its engineered stability and reduced amyloidogenicity compared to native amylin, pramlintide provides a unique reference point for studying peptide aggregation phenomena. Researchers utilize it to investigate the molecular mechanisms of amyloid fibril formation, the structural features that govern aggregation propensity, and the cellular consequences of peptide misfolding. These studies are critical for understanding the pathogenesis of islet amyloidosis and for developing strategies to mitigate protein aggregation in peptide-based drug development.
Amylin receptor pharmacology: Pramlintide is frequently employed as a selective agonist in assays designed to characterize amylin receptor subtypes, signal transduction pathways, and ligand-receptor interactions. Its well-defined pharmacological profile enables precise evaluation of receptor binding kinetics, downstream signaling cascades, and cross-talk with other peptide hormone receptors. These investigations facilitate the identification of novel receptor modulators, advance the understanding of amylinergic signaling, and support the development of targeted research tools.
Peptide formulation and delivery research: The altered physicochemical properties of pramlintide relative to native amylin make it a valuable model for studies focused on peptide formulation, stability, and delivery. Researchers leverage its enhanced solubility and aggregation resistance to optimize formulation strategies for peptide-based compounds, assess the impact of excipients and delivery vehicles, and evaluate storage and handling conditions. Such work is essential for improving the manufacturability, shelf-life, and usability of peptide research reagents and investigational molecules.
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
2. Emu oil in combination with other active ingredients for treating skin imperfections
3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
4. Cationic cell-penetrating peptides are potent furin inhibitors
5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More